Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

MLA

J. Tabernero, et al. Management of Adverse Events from the Treatment of Encorafenib plus Cetuximab for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer: Insights from the BEACON CRC Study. Dec. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3f55f353f7d3d33539bbcc2d27211073&authtype=sso&custid=ns315887.

APA

J. Tabernero, L. Velez, T.L. Trevino, A. Grothey, R. Yaeger, E. Van Cutsem, H. Wasan, J. Desai, F. Ciardiello, T. Yoshino, A. Gollerkeri, K. Maharry, J. Christy-Bittel, & S. Kopetz. (2021). Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.

Chicago

J. Tabernero, L. Velez, T.L. Trevino, A. Grothey, R. Yaeger, E. Van Cutsem, H. Wasan, et al. 2021. “Management of Adverse Events from the Treatment of Encorafenib plus Cetuximab for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer: Insights from the BEACON CRC Study,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3f55f353f7d3d33539bbcc2d27211073&authtype=sso&custid=ns315887.